CIDeRplusGeneral Information:
| Id: | 6,356 |
| Diseases: |
Prostate cancer
- [OMIM]
|
| Homo sapiens | |
| DU-145 prostate cancer cell | |
| article | |
| Reference: | Makarevic J et al.(2014) Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells J. Cell. Mol. Med. 18: 1460-1466 [PMID: 24779401] |
Interaction Information:
| Comment | Valproic acid serves as a pan HDAC inhibitor. To allow a more precise analysis of the mode of action underlying HDAC-triggered mTOR modulation, HDAC1 or HDAC2 was knocked down. Both strategies modified the mTOR pathway. However, H4 acetylation was elevated only in those cells incubated with HDAC1 siRNA, whereas aH3 (histone H3 acetylation) was up-regulated by both HDAC1 and HDAC2 siRNA. This observation may point to a major role of aH3 in initiating the link to mTOR. |
|
Formal Description Interaction-ID: 59552 |
gene/protein decreases_activity of process |
| Drugbank entries | Show/Hide entries for HDAC1 |
| Comment | Valproic acid serves as a pan HDAC inhibitor. To allow a more precise analysis of the mode of action underlying HDAC-triggered mTOR modulation, HDAC1 or HDAC2 was knocked down. Both strategies modified the mTOR pathway. However, H4 acetylation was elevated only in those cells incubated with HDAC1 siRNA, whereas aH3 was up-regulated by both HDAC1 and HDAC2 siRNA. This observation may point to a major role of aH3 in initiating the link to mTOR. |
|
Formal Description Interaction-ID: 59553 |
gene/protein decreases_activity of process |
| Drugbank entries | Show/Hide entries for HDAC1 |
| Comment | Valproic acid serves as a pan HDAC inhibitor. To allow a more precise analysis of the mode of action underlying HDAC-triggered mTOR modulation, HDAC1 or HDAC2 was knocked down. Both strategies modified the mTOR pathway. However, H4 acetylation was elevated only in those cells incubated with HDAC1 siRNA, whereas aH3 was up-regulated by both HDAC1 and HDAC2 siRNA. This observation may point to a major role of aH3 in initiating the link to mTOR. |
|
Formal Description Interaction-ID: 59554 |
gene/protein decreases_activity of process |
| Drugbank entries | Show/Hide entries for HDAC2 |
| Comment | HDAC1 and HDAC2 knock-down revealed that the interaction with the mTOR system is initiated by histone H3 acetylation. |
|
Formal Description Interaction-ID: 59555 |
process increases_activity of gene/protein |
| Drugbank entries | Show/Hide entries for MTOR |
| Comment | DU-145 prostate cancer cells were treated with insulin-like growth factor (IGF) to activate the Akt-mTOR cascade or with the HDAC-inhibitor valproic acid (VPA) to induce histone H3 and H4 acetylation (aH3, aH4). |
|
Formal Description Interaction-ID: 59556 |
|
| Drugbank entries | Show/Hide entries for IGF1 |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59557 |
|
| Drugbank entries | Show/Hide entries for IGF1 or MTOR |
| Comment | VPA (HDAC-inhibitor valproic acid) treatment up-regulated histone acetylation, but also activated mTOR-Akt signalling. |
|
Formal Description Interaction-ID: 59558 |
drug/chemical compound increases_activity of process AKT/TOR signaling |
| Drugbank entries | Show/Hide entries for Valproic acid |
| Comment | DU-145 prostate cancer cells were treated with insulin-like growth factor (IGF) to activate the Akt-mTOR cascade or with the HDAC-inhibitor valproic acid (VPA) to induce histone H3 and H4 acetylation (aH3, aH4). |
|
Formal Description Interaction-ID: 59565 |
drug/chemical compound increases_activity of process |
| Drugbank entries | Show/Hide entries for Valproic acid |
| Comment | DU-145 prostate cancer cells were treated with insulin-like growth factor (IGF) to activate the Akt-mTOR cascade or with the HDAC-inhibitor valproic acid (VPA) to induce histone H3 and H4 acetylation (aH3, aH4). |
|
Formal Description Interaction-ID: 59566 |
drug/chemical compound increases_activity of process |
| Drugbank entries | Show/Hide entries for Valproic acid |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59567 |
|
| Drugbank entries | Show/Hide entries for IGF1 |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59569 |
|
| Drugbank entries | Show/Hide entries for IGF1 |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59571 |
|
| Drugbank entries | Show/Hide entries for IGF1 |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59573 |
|
| Drugbank entries | Show/Hide entries for IGF1 or AKT1 |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59574 |
gene/protein increases_activity of process |
| Drugbank entries | Show/Hide entries for IGF1 |
| Comment | Insulin-like growth factor (IGF) activated mTOR, Rictor, Raptor, p70s6k and Akt, but also enhanced histone H3 and H4 acetylation (aH3 and aH4). |
|
Formal Description Interaction-ID: 59575 |
gene/protein increases_activity of process |
| Drugbank entries | Show/Hide entries for IGF1 |